Gauthier-Vasserot Alexandra, Thauvin-Robinet Christel, Bruel Ange-Line, Duffourd Yannis, St-Onge Judith, Jouan Thibaud, Rivière Jean-Baptiste, Heron Delphine, Donadieu Jean, Bellanné-Chantelot Christine, Briandet Claire, Huet Frédéric, Kuentz Paul, Lehalle Daphné, Duplomb-Jego Laurence, Gautier Elodie, Maystadt Isabelle, Pinson Lucile, Amram Daniel, El Chehadeh Salima, Melki Judith, Julia Sophia, Faivre Laurence, Thevenon Julien
Service de Pédiatrie 1, Hôpital d'Enfants, CHU, Dijon, France.
Centre de Génétique et Centre de Référence Maladies Rares « Anomalies du Développement et Syndromes Malformatifs de l'Interrégion Est », Hôpital d'Enfants, CHU, Dijon, France.
Am J Med Genet A. 2017 Jan;173(1):62-71. doi: 10.1002/ajmg.a.37969. Epub 2016 Sep 12.
Neutropenia can be qualified as congenital when of neonatal onset or when associated with extra-hematopoietic manifestations. Overall, 30% of patients with congenital neutropenia (CN) remain without a molecular diagnosis after a multidisciplinary consultation and tedious diagnostic strategy. In the rare situations when neutropenia is identified and associated with intellectual disability (ID), there are few diagnostic hypotheses to test. This retrospective multicenter study reports on a clinically heterogeneous cohort of 10 unrelated patients with CN associated with ID and no molecular diagnosis prior to whole-exome sequencing (WES). WES provided a diagnostic yield of 40% (4/10). The results suggested that in many cases neutropenia and syndromic manifestations could not be assigned to the same molecular alteration. Three sub-groups of patients were highlighted: (i) severe, symptomatic chronic neutropenia, detected early in life, and related to a known mutation in the CN spectrum (ELANE); (ii) mild to moderate benign intermittent neutropenia, detected later, and associated with mutations in genes implicated in neurodevelopmental disorders (CHD2, HUWE1); and (iii) moderate to severe intermittent neutropenia as a probably undiagnosed feature of a newly reported syndrome (KAT6A). Unlike KAT6A, which seems to be associated with a syndromic form of CN, the other reported mutations may not explain the entire clinical picture. Although targeted gene sequencing can be discussed for the primary diagnosis of severe CN, we suggest that performing WES for the diagnosis of disorders associating CN with ID will not only provide the etiological diagnosis but will also pave the way towards personalized care and follow-up. © 2016 Wiley Periodicals, Inc.
当中性粒细胞减少症在新生儿期发病或与造血外表现相关时,可被认定为先天性。总体而言,30%的先天性中性粒细胞减少症(CN)患者在经过多学科会诊和繁琐的诊断策略后仍未得到分子诊断。在罕见的情况下,当确诊中性粒细胞减少症并伴有智力残疾(ID)时,可供检测的诊断假设很少。这项回顾性多中心研究报告了一组临床异质性队列,该队列由10名无亲缘关系的患者组成,他们患有与ID相关的CN,且在全外显子组测序(WES)之前未得到分子诊断。WES的诊断率为40%(4/10)。结果表明,在许多情况下,中性粒细胞减少症和综合征表现不能归因于相同的分子改变。突出了三个患者亚组:(i)严重的、有症状的慢性中性粒细胞减少症,在生命早期被检测到,与CN谱系中的已知突变(ELANE)有关;(ii)轻度至中度的良性间歇性中性粒细胞减少症,在后期被检测到,与神经发育障碍相关基因(CHD2、HUWE1)的突变有关;(iii)中度至重度间歇性中性粒细胞减少症,可能是一种新报告综合征(KAT6A)的未被诊断特征。与似乎与综合征形式的CN相关的KAT6A不同,其他报告的突变可能无法解释整个临床情况。虽然对于严重CN的初步诊断可以讨论靶向基因测序,但我们建议,对与ID相关的CN疾病进行WES诊断不仅能提供病因诊断,还将为个性化护理和随访铺平道路。© 2016威利期刊公司